About 31 results found for searched term "CK2-IN-6" (0.103 seconds)
| Cat.No. | Name | Target |
|---|---|---|
| M41590 | ROCK2-IN-6 hydrochloride | ROCK |
| ROCK2-IN-6 hydrochloride is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research. | ||
| M41591 | ROCK2-IN-6 | ROCK |
| ROCK2-IN-6 is a selective ROCK2 inhibitor, can be used for ROCK mediated diseases, autoimmune diseases and inflammation research. | ||
| M45302 | CK2-IN-6 | Casein Kinase |
| CK2-IN-6 is a potent protein kinase CK2 inhibitor for use in studies related to cancer as well as other kinase-associated conditions, including inflammation, pain, and certain immune disorders. | ||
| M1817 | Y-27632 dihydrochloride | ROCK |
| Y27632; Y-27632 2HCl | ||
| Y-27632 is a potent, selective inhibitor of Rho-associated protein kinases (ROCK) with IC50 values of 140-220 nM for ROCK1 and ROCK2. In addition, Y-27632 inhibited LPA-induced entosis. | ||
| M3412 | Propafenone hydrochloride | Sodium Channel |
| Propafenone HCl is a sodium-channel blocker that also has a high affinity for β-receptors (IC50 = 32 nM). It blocks transient outward potassium current (Ito) and sustained delayed rectifier K+ current (Isus) with IC50 values of 4.9 μM and 8.6 μM, respectively.In addition, Propafenone inhibits the proliferation of esophageal cancer by inducing mitochondrial dysfunction and apoptosis. | ||
| M1545 | Infliximab | TNF Receptor |
| Remicade; Avakine; CT-P13 | ||
| Infliximab is a purified, recombinant DNA-derived chimeric human-mouse IgG monoclonal antibody that blocks TNF-α interaction with TNF-α receptor 1 (TNFR1) and TNFR2. For the treatment of autoimmune diseases. Infliximab is available in BALB/ C or C57/Bl6 mice. | ||
| M4079 | (R)Ginsenoside-Rh2 | MMP |
| 20(R)-Ginsenoside Rh2, a matrix metalloproteinase (MMP) inhibitor, acts as an anti-proliferative agent in cells. It has anticancer effects by blocking cell proliferation and causing G1 phase arrest. 20(R)-Ginsenoside Rh2 induces apoptosis and has anti-inflammatory and antioxidant activities. 20(R)-Ginsenoside Rh2 inhibited the replication and proliferation of mouse and human γ herpevirus 68 (MHV-68) with an IC50 of 2.77 μM against mouse MHV-68. | ||
| M4090 | Ginsenoside-Rg5 | IGF-1R |
| Ginsenoside Rg5 is the main ingredient of red ginseng. Ginsenoside Rg5 blocks the binding of IGF-1 to its receptor with an IC50 of about 90 nM. Ginsenoside Rg5 also inhibited COX-2 mRNA expression by inhibiting DNA binding activity of NF-κB P65. | ||
| M4583 | (-)-Maackiain | Parasite |
| l-Maackiain | ||
| Maackiain (DL-Maackiain) was separated from Maackia amurensis Rupr. Et Maxim. Maackiain (DL-Maackiain) is a larval insecticide against Aedes aegypti with a LD50 of 21.95 μg/ mL. Maackiain (DL-Maackiain) induces DNA fragmentation into oligonucleosome size fragments, similar to apoptotic characteristics such as HL-60 cells. | ||
| M5123 | Y-39983 dihydrochloride | ROCK |
| Y-33075 dihydrochloride | ||
| Y-39983 (Y-33075) dihydrochloride is a selective ROCK inhibitor with an IC50 of 3.6 nM, derived from Y-27632, inhibited ROCK more potently than Y-27632. | ||
| M6102 | Pembrolizumab | PD-1/PD-L1 |
| Lambrolizumab; MK-3475 | ||
| Pembrolizumab (pembrolizumab) is a humanized anti-PD-1 monoclonal antibody that blocks the interaction between PD-1 and its ligands PD-L1 and PD-L2. It has immune checkpoint inhibitory activity and antitumor activity. MW: 146.286 KD.(Pembrolizumab does not recognize murine PD-1 protein, humanized mice or mice expressing human PD-1 gene are required). | ||
| M8121 | PD-85639 | Others |
| PD-85639 (PD85,639) is a voltage-gated sodium (Na+) channel blocker (75% in 10 min & >95% in 25 min blockage of Na+ current by 25 μM PD85,639; whole-cell patch clamp using primary rat brain neurons) that is shown to target rat brain Nav1. | ||
| M8747 | Synta66 | Calcium Channel |
| Synta66 (S66) is a CRAC (Ca2+ release-activated Ca2+) channel inhibitor that blocks SOCE (store-operated Ca2+ entry) upon Ca2+ depletion from intracellular stores by thapsigargin in human vascular smooth muscle cells (VSMCs) with high potency (IC50 = 26 nM & 43 nM based on maximum Ca2+ level & rate of increase, respectly). | ||
| M20381 | WAY-302713-A | Casein Kinase |
| CK2α-IN-1 | ||
| WAY-302713-A is a selective, non-ATP-competitive CK2α inhibitor (IC50=7.0 µM; Ki=1.6 µM) for cancer-related studies. | ||
| M20386 | WAY-297674 | Casein Kinase |
| CK2-IN-4 | ||
| WAY-297674 is a protein kinase (CK2) inhibitor (IC50=8.6 µM). It can be used in studies related to cancer, viral infections, and glomerulonephritis. | ||
| M21033 | CK1-IN-1 | Casein Kinase |
| PUN51207, Compound 1C | ||
| CK1-IN-1 (PUN51207, Compound 1C) is an inhibitor of casein kinase 1 (CK1) with IC50 of 15 nM, 16 nM and 73 nM for CK1δ, CK1ε and p38α MAPK, respectively. | ||
| M27869 | CCT241161 | Raf |
| CCT241161 is an orally active pan-RAF inhibitor with IC50s of 3, 6, 10, 15 and 30 nM for LCK, CRAF, SRC, V600E-BRAF and BRAF, respectively. CCT241161 shows good activity to in BRAF and NRAS mutant melanomas. CCT241161 also exhibits anticancer cell proliferative activity. | ||
| M28240 | AZD4320 | Bcl-2 |
| AZD4320 is a novel BH3-mimicking dual BCL2/BCLxL inhibitor with IC50s of 26 nM, 17 nM, and 170 nM for KPUM-MS3, KPUM-UH1, and STR-428 cells, respectively. | ||
| M28436 | Zidebactam | Antibiotic |
| WCK-5107 | ||
| Zidebactam (WCK-5107) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL. | ||
| M28769 | PDK1-IN-RS2 | PDK1 |
| PDK1-IN-RS2 is a mimic of peptide docking motif (PIFtide) and is a substrate-selective PDK1 inhibitor with a Kd of 9 μM. PDK1-IN-RS2 suppresses the activation of the downstream kinases S6K1 by PDK1. | ||
| M28823 | Zidebactam sodium salt | Antibiotic |
| WCK-5107 sodium salt | ||
| Zidebactam sodium salt (WCK-5107 sodium salt) is a potent β-lactamase inhibitor. Zidebactam also is a penicillin-binding protein2 (PBP2) inhibitor with an IC50 of 0.26 μg/mL. | ||
| M29195 | Nastorazepide | Cholecystokinin Receptor |
| Z-360 | ||
| Nastorazepide (Z-360) is a selective, orally available, 1,5-benzodiazepine-derivative gastrin/cholecystokinin 2 (CCK-2) receptor antagonist with potential antineoplastic activity. Target：CCK-2 in vitro: Z-360 binds to the gastrin/CCK-2 receptor, thereby preventing receptor activation by gastrin, a peptide hormone frequently associated with the proliferation of gastrointestinal and pancreatic tumor cells. Check for active clinical trials or closed clinical trials using this agent. in vivo: Z-360 is a novel orally active CCK-2/gastrin receptor antagonist, significantly inhibits the growth of subcutaneous xenografts of human pancreatic tumor cells in mice, and that Z-360 combined with gemcitabine prolonged survival in a pancreatic carcinoma orthotopic xenograft mice. | ||
| M29455 | DDO-7263 | Keap1-Nrf2 |
| DDO-7263, a 1,2,4-Oxadiazole derivative, is a potent Nrf2-ARE activator. DDO-7263 upregulates Nrf2 through binding to Rpn6 to block the assembly of 26S proteasome and the subsequent degradation of ubiquitinated Nrf2. DDO-7263 induces Nrf2 translocation into the nucleus. DDO-7263 inhibits of NLRP3 inflammasome activation. DDO-7263 exerts anti-inflammatory activity and has the potential for neurodegenerative diseases research, such as Parkinson's disease (PD). | ||
| M29943 | T-2 Triol | Metabolite/Endogenous Metabolite |
| T-2 Triol is a trichothecene mycotoxin derived by the metabolism of T-2 toxin. It is less toxic than T-2 toxin. T-2 Triol major metabolites are evaluated in broiler chickens with Half-lives (t1/2λz), Peak plasma concentrations (Cmax) and Tmax values of 9.6 mins, 563 ng/ml , 2.5 mins, respectively. | ||
| M30242 | Methoxy-PEPy | GluR |
| Methoxy-PEPy is a potent and highly selective mGlu5 receptor antagonist with IC50 of 1 nM. IC50 value: 1 nM [1] Target: mGlu5R inhibitor Administration of [3H]methoxy-PEPy (50 microCi/kg i.v.) to mGlu5 receptor-deficient mice revealed binding at background levels in forebrain, whereas wild-type mice exhibited 14-fold higher binding in forebrain relative to cerebellum . The calcium transients stimulated by these agonists were potently inhibited by reference allosteric mGlu5 antagonists - 2-methyl-6-(phenylethynyl)pyridine (MPEP), 3-[(2-methyl-1,3-thiazol-4-yl)ethynyl]pyridine (MTEP) and 3-methoxy-5-(pyridine-2-ylethynyl)pyridine (methoxy-PEPy) (IC(50) ranges: 0.8-66 nM) . | ||
| M30426 | Bepridil | Calcium Channel |
| (±)-Bepridil; Org 5730 | ||
| Bepridil ((±)-Bepridil) is a calcium channel blocking agent used as antiarrhythmic agent. Bepridil inhibits both calcium and sodium currents, has research potential in certain ischemia-induced ventricular arrhythmias. Bepridil also has strong inhibition of SARS-CoV-2 from entry and replication inside Vero E6 and A549 cells. | ||
| M30485 | (2R/S)-6-PNG | Calcium Channel |
| 6-Prenylnaringenin; (±)-6-Prenylnaringenin | ||
| (2R/S)-6-PNG (6-Prenylnaringenin) is a potent and reversible Cav3.2 T-type Ca2+ channels (T-channels) blocker. (2R/S)-6-PNG can penetrate the blood-brain barrier (BBB). (2R/S)-6-PNG suppresses neuropathic and visceral pain in mice. | ||
| M30754 | PT-262 | ROCK |
| PT-262 is a potent ROCK inhibitor with an IC50 value of around 5 μM. PT-262 induces the loss of mitochondrial membrane potential and elevates the caspase-3 activation and apoptosis. PT-262 inhibits the ERK and CDC2 phosphorylation via a p53-independent pathway. PT-262 blocks cytoskeleton function and cell migration. PT-262 has anti-cancer activity. | ||
| M30952 | Lck inhibitor 2 | Src-bcr-Abl |
| Lck inhibitor 2 is a bis-anilinopyrimidine inhibitor of tyrosine kinases including LCK, BTK, LYN, SYK, and TXK. The IC50 values are 13nM, 9nM, 3nM, 26nM and 2nM for Lck, Btk, Lyn, Btk and Txk respectively IC50 Value: 13 nM(Lck) [1] Target: Src family kinase Lck inhibitor 2(Compound 9) inhibited 48 kinases with %control < 1 (33 of them tyrosine kinases, almost half of the 71 tyrosine kinases in the panel). A further 27 kinases were bound with %control < 10. Kd values for 16 kinases were determined and found to be below 100 nM. These included TXK (10 nM). | ||
| M31200 | CK7 | CDK |
| CK-7 | ||
| CK7 is a Cdk2/9 inhibitor, which can be used for the synthesis of Nek1 inhibitor BSc5231 and BSc5367. | ||
| M41415 | CK1-IN-2 | Casein Kinase |
| CK1-IN-2 is a potent CK1 inhibitor with an IC50 values of 123, 19.8, 26.8, 74.3 nM for CK1a, CK1d, CK1e, p38a, respectively. | ||
Products are for research use only. Not for human use. We do not sell to patients.
© Copyright 2010-2024 AbMole BioScience. All Rights Reserved.
